2012, Número 1
<< Anterior Siguiente >>
Rev Cubana Farm 2012; 46 (1)
Las β-(1→3)-glucanas: moléculas inmunomoduladoras contaminantes de productos farmacéuticos
Pardo RZ, Perdomo MR
Idioma: Español
Referencias bibliográficas: 45
Paginas: 105-116
Archivo PDF: 81.21 Kb.
RESUMEN
Se realizó una búsqueda bibliográfica utilizando la base de datos Pubmed con énfasis
en los artículos publicados en la última década. Como descriptores se utilizaron los
siguientes: glucans, glucans recognition, glucans biological activitiy, glucans
pharmaceuticals. Con la información disponible se realizó un análisis de los principales
aspectos relacionados con el tema, que se exponen en el presente trabajo. Las β-
(1→3)-glucanas son polímeros de glucosa que se encuentran mayoritariamente en la
pared celular de hongos, levaduras y plantas. Se consideran patrones moleculares
asociados a patógenos y son reconocidas por varios receptores, siendo la dectina-1 el
principal receptor de reconocimiento de estas estructuras. Sus propiedades
inmunomoduladoras han sido informadas por varios autores. Se ha demostrado que
potencian y sinergizan la acción de ligandos de Toll like receptors sobre la liberación
de citoquinas proinflamatorias, aunque también han mostrado un perfil
antiinflamatorio, cuestión que depende en gran medida de sus características
estructurales. Las β-(1→3)-glucanas son contaminantes importantes provenientes de
los filtros de acetato de celulosa que se utilizan en la clarificación de parenterales
hemoderivados, por tanto, es necesario estudiar las consecuencias de la presencia de
estas moléculas inmunomoduladoras en inyectables. En esta revisión se resumen
aspectos relacionados con el reconocimiento y actividad biológica de las β-(1→3)-
glucanas y se profundiza en estudios relacionados con su presencia en hemoderivados
como principal contaminante. Finalmente se destaca la utilidad de la Prueba de
Activación de Monocitos en la detección de las β-(1→3)-glucanas en parenterales.
REFERENCIAS (EN ESTE ARTÍCULO)
Brown G, Gordon S. Immune recognition of fungal b-glucans. Cell Microbiol. 2005;7(4):471.9.
Medzhitov R, Janeway C. Innate Immunity. N Engl J Med. 2000;343:338-44.
Soltanian S, Stuyven E, Cox E, Sorgeloos P, Bossier P. Beta-glucans as immunostimulant in vertebrates and invertebrates. Crit Rev Microbiol. 2009;35(2):109-38.
Usami M, Ohata A, Horiuchi T, Nagasawa K, Wakabayashi T, Tanaka S. Positive (1→3)-β-D-glucan in blood components and release of (1→3)-β-D-glucan from depthtype membrane filters for blood processing. Transfusion. 2002;42:1189-95.
Nagasawa K, Yano Y, Kitabayashi G, Morimoto H, Yamada Y, Ohata O, et al. Experimental proof of contamination of blood components by (1→3)-β-D-glucan caused by filtration with cellulose filters in the manufacturing process. J Artif Organs. 2003;6:49-54.
Ohata A, Usami M, Horiuchi T, Nagasawa K. Release of (1→3)-β-D-Glucan from Depth-type Membrane Filters and Their in vitro Effects on Proinflammatory Cytokine Production. Artificial Organs. 2003;27(8):728-35.
Ochiai M, Yamamoto A, Naito S, Maeyama J, Masumi A, Hamaguchi I, et al. Applicability of bacterial endotoxins test to various blood products by the use of endotoxin-specific lysates. Biologicals. 2010:38:629-36.
Buchacher A, Krause D, Wiry G, Weinberger J. Elevated Endotoxin Levels in Human Intravenous Immunoglobulin Concentrates Caused by (1->3)-{beta}-D-Glucans. PDA J Pharm Sci Technol. 2010;64:536-44.
Brown G, Gordon S. A new receptor for b-glucans. Nature. 2001;413:36-7.
Tsoni V, Brown G. β-Glucans and Dectin-1. Ann NY Acad Sci. 2008;1143:45-60.
Goodridge H, Wolf A, Underhill D. Beta-glucan recognition by the innate immune system. Immunol Rev. 2009;230(1):38-50.
Reid D, Gow N, Brown G. Pattern recognition: recent insights from Dectin-1. Curr Opin Immunol. 2009;21(1):30-7.
Taylor P, Brown G, Reid D, Martínez-Pomares L, Gordon S, Wong S. The betaglucan receptor, Dectin-1, is predominantly expressed on the surface of cells of the monocyte-macrophage and neutrophyl line cells. J Immunol .2002;269:3876-82.
Willment J, Brown G, Gordon S. Characterisation of the human beta-glucan receptor and its alternatively spliced isoforms. J Biol Chem. 2001;276:43818-23.
Brown G, Gordon S. Fungal beta-glucans and mammalian Immunity. Immunity. 2003;19:311-5.
Hoekstra M, Van Berkel TJC, Van Eck M. Scavenger receptor BI: A multi-purpose player in cholesterol and steroid metabolism. World J Gastroenterol. 2010;16(47):5916-24.
Rice P, Kelley J, Kogan G, Ensley H, Kalbfleisch J, Browder I, et al. Human monocyte scavenger receptors are pattern recognition receptors for (1→3)-beta-Dglucans. J Leukoc Biol. 2002;72:140-6.
Thornton B, Vetvicka V, Pitman M, Goldman R, Ross G. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol. 1996;156:1235-46.
van Bruggen R, Drewniak A, Jansen M, van Houdt M, Roos D, Chapel H, et al. Complement receptor 3, not Dectin-1, is the major receptor on human neutrophils for beta-glucan-bearing particles. Mol Immunol. 2009;47(2-3):575-81.
Hahn P, Evans S, Kottom T, Standing J, Pagano R, Limper A. Pneumocystis carinii cell wall beta-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J Biol Chem. 2003;278:2043-50.
Herre J, Gordon S, Brow, GD. Dectin-1 and its role in the recognition of betaglucans by macrophages. Mol Immunol. 2004;40:86976.
Williams D, Li C, Ha T, Ozment-Skelton T, Kalbfleisch J, Preiszner J, Brooks L, et al. Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis. J Immunol. 2004;172:44956.
Engstad Ch, Engstad R, Olsen J, Osterud B. The effect of soluble h-1,3-glucan and lipopolysaccharide on cytokine production and coagulation activation in whole blood. Int Immunopharmacol. 2002;2:1585-97.
Kikkert R, Bulder I, de Groot E, Aarden L, Finkelman M. Potentiation of Toll-like receptor-induced cytokine production by (1→3)-β-D-glucans: implications for the monocyte activation test. J Endotoxin Res. 2007;13(3):140-9.
Nakagawa Y, Ohno N, Murai T. Suppression by Candida albicans beta-glucan of cytokine release from activated human monocytes and from T cells in the presence of monocytes. J Infect Dis. 2003;187:710-13.
Luhm J, Langenkamp U, Hensel J, Frohn Ch, Brand G, Hennig H, et al. β-(1→3)-Dglucan modulates DNA binding of nuclear factors κB, AT and IL-6 leading to an antiinflammatory shift of the IL-1β/IL-1receptor antagonist ratio. BMC Immunol. 2006;7:5.
Suda M, Ohno N, Adachi Y, Yadomae T. Tissue distribution of intraperitoneally administered (1→3)-beta-D-glucan (SSG), a highly branched antitumor glucan, in mice. J Pharmacobiodyn. 1992;15:417-26.
Suda M, Ohno N, Hashimoto T, Koizumi K, Adachi Y, Yadomae T. Kupffer cells play important roles in the metabolic degradation of a soluble anti-tumor (1→3)-beta-Dglucan, SSG, in mice. FEMS Immunol Med Microbiol. 1996;15:93-100.
Miura T, Ohno N, Miura N, Shimada S, Yadomae T. Inactivation of a particle β- glucan by proteins in plasma and serum. Biol Pharm Bull 1997;20:1103-7.
Murphy E, Davis J, Carmichael M. Immune modulating effects of β-glucan. Curr Opin Clin Nutr Metab Care. 2010;13(6):656-61.
Hong F, Yan J, Baran J, Allendorf D, Hansen R, Ostroff G, et al. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol. 2004;173:797-806.
Rice P, Adams E, Ozment-Skelton T, Gonzalez A, Goldman M, Lockhart B, et al. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J Pharmacol Exp Ther. 2005;314:1079-86.
Li B, Cai Y, Qi C, Hansen R, Ding C, Mitchell TC, Yan J. Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. Clin Cancer Res. 2010;16(21):5153-64.
Takahashi H, Ohno N, Adachi Y, Yadomae T. Association of immunological disorders in lethal side effect of NSAIDs on beta-glucan-administered mice. FEMS Immunol Med Microbiol. 2001;31:1-14.
Douwes J. (1→3)-Beta-D-glucans and respiratory health: a review of the scientific evidence. Indoor Air. 2005;15:160-9.
Yoshitomi H, Sakaguchi N, Kobayashi K, Brown GD, Tagami T, Sakihama T, et al. A role for fungal β-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J Exp Med. 2005;201:949-60.
Yoshida K, Nakajima M, Yamasaki M, Kitano Y, Niki Y, Ohsawa G, et al. Investigation of the influence of hemodialysis membranes and factors associated with hemodialysis on serum (1→3)-β-D-glucan. Kansenshogaku Zasshi. 1998;72:245-8.
Kanda H, Kubo K, Hamasaki K, Kanda Y, Nakao A, Kitamura T, et al. Influence of various hemodialysis membranes on the plasma (1→3)-β-D-glucan level. Kidney Int. 2001;60:31923.
Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A. Elevation of blood (1→3)-β-D-glucan concentrations in hemodialysis patients. Nephron. 2001;89:15-9.
Hoffman O, Olson E, Limper A. Fungal beta-glucans modulate macrophage release of tumor necrosis factor-alpha in response to bacterial lipopolysaccharide. Immunol Lett. 1993;37:19-25.
Masihi K, Madaj K, Hintelmann H, Gast G, Kaneko Y. Down-regulation of tumor necrosis factor-alpha, moderate reduction of interleukin-1beta, but not interleukin-6 or interleukin-10, by glucan immunomodulators curdlan sulfate and lentinan. Int J Immunopharmacol. 1997;19:463-8.
Pearson F, Bohon J, Lee W, Bruszer G, Sagona M, Jakubowski G, et al. Characterization of Limulus Amoebocyte Lysate-Reactive Material from Hollow-Fiber Dialyzers. Environ Microbiol Rep. 1984;48:1189-96.
Perdomo-Morales R, Pardo-Ruiz Z, Spreitzer I, Lagarto A, Montag T. Monocyte Activation Test (MAT) reliably detects pyrogens in parenteral formulations of Human Serum Albumin. ALTEX. 2011;28:227-35.
Finkelman M. Glucatell™-A New Kit for Quantitative Determination of (1→3)-β-DGlucan. LAL Update. 2001;19:1-4.
Tsuchiya M, Asahi N, Suzuoki F, Ashida M, Matsuura S. Detection of peptidoglycan and L-glucan with silkworm larvae plasma test. FEMS Immunol Med Microbiol. 1996;15:129-34.